Autolus Non Current Liabilities Total vs Return On Assets Analysis

AUTL Stock

USD 4.19 0.08 1.95%

Autolus Therapeutics financial indicator trend analysis is way more than just evaluating Autolus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Autolus Therapeutics is a good investment. Please check the relationship between Autolus Therapeutics Non Current Liabilities Total and its Return On Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

Non Current Liabilities Total vs Return On Assets

Non Current Liabilities Total vs Return On Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Autolus Therapeutics Non Current Liabilities Total account and Return On Assets. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Autolus Therapeutics' Non Current Liabilities Total and Return On Assets is -0.55. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Return On Assets in the same time period over historical financial statements of Autolus Therapeutics, assuming nothing else is changed. The correlation between historical values of Autolus Therapeutics' Non Current Liabilities Total and Return On Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Autolus Therapeutics are associated (or correlated) with its Return On Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Return On Assets has no effect on the direction of Non Current Liabilities Total i.e., Autolus Therapeutics' Non Current Liabilities Total and Return On Assets go up and down completely randomly.

Correlation Coefficient

-0.55

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Non Current Liabilities Total

Return On Assets

A profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets.

Most indicators from Autolus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Autolus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.Enterprise Value is expected to rise to about 882.2 M this year, although the value of Selling General Administrative will most likely fall to about 7.2 M.

	2021	2022	2024 (projected)
Depreciation And Amortization	7.4M	6.6M	4.9M
Interest Income	1.7M	11.9M	627K

Depreciation And Amortization Interest Income

Autolus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Other Current Assets	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity
Total Assets		0.62	0.95	0.9	0.94	-0.78	0.01	0.98	0.94	0.35	0.76	0.99	-0.81	0.89	0.77	0.66	0.66	0.73	-0.94	0.76	-0.07	0.98	0.63	0.63	0.9	0.76
Other Current Liab	0.62		0.72	0.3	0.46	-0.74	-0.01	0.59	0.52	0.36	0.89	0.59	-0.34	0.86	0.23	0.28	0.49	0.32	-0.59	0.34	-0.2	0.59	0.4	0.45	0.43	0.74
Total Current Liabilities	0.95	0.72		0.75	0.83	-0.88	-0.12	0.88	0.96	0.55	0.87	0.9	-0.84	0.95	0.78	0.74	0.64	0.79	-0.81	0.8	-0.1	0.88	0.66	0.68	0.83	0.81
Total Stockholder Equity	0.9	0.3	0.75		0.96	-0.47	0.19	0.94	0.81	0.11	0.42	0.93	-0.72	0.61	0.75	0.56	0.58	0.64	-0.91	0.67	-0.03	0.93	0.5	0.48	0.91	0.48
Net Tangible Assets	0.94	0.46	0.83	0.96		-0.57	0.23	0.96	0.83	0.24	0.56	0.96	-0.73	0.72	0.69	0.65	0.49	0.71	-0.92	0.74	-0.17	0.95	0.62	0.59	0.97	0.55
Retained Earnings	-0.78	-0.74	-0.88	-0.47	-0.57		0.43	-0.68	-0.83	-0.58	-0.96	-0.72	0.72	-0.93	-0.6	-0.54	-0.6	-0.58	0.63	-0.58	-0.09	-0.68	-0.49	-0.53	-0.54	-0.93
Accounts Payable	0.01	-0.01	-0.12	0.19	0.23	0.43		0.07	-0.14	-0.09	-0.25	0.05	0.36	-0.2	-0.06	-0.17	-0.18	-0.16	-0.1	-0.11	-0.29	0.05	-0.13	-0.19	0.25	-0.24
Cash	0.98	0.59	0.88	0.94	0.96	-0.68	0.07		0.86	0.17	0.67	1.0	-0.75	0.83	0.68	0.59	0.64	0.67	-0.98	0.69	-0.12	1.0	0.6	0.61	0.9	0.66
Net Receivables	0.94	0.52	0.96	0.81	0.83	-0.83	-0.14	0.86		0.56	0.77	0.89	-0.86	0.86	0.91	0.74	0.67	0.79	-0.79	0.8	0.07	0.86	0.59	0.6	0.83	0.79
Other Current Assets	0.35	0.36	0.55	0.11	0.24	-0.58	-0.09	0.17	0.56		0.59	0.22	-0.4	0.46	0.55	0.52	0.13	0.47	-0.03	0.48	0.17	0.15	0.23	0.23	0.35	0.54
Total Liab	0.76	0.89	0.87	0.42	0.56	-0.96	-0.25	0.67	0.77	0.59		0.69	-0.61	0.95	0.5	0.48	0.56	0.52	-0.63	0.53	-0.03	0.67	0.48	0.52	0.54	0.92
Total Current Assets	0.99	0.59	0.9	0.93	0.96	-0.72	0.05	1.0	0.89	0.22	0.69		-0.77	0.85	0.72	0.61	0.66	0.69	-0.97	0.71	-0.09	1.0	0.61	0.61	0.9	0.69
Intangible Assets	-0.81	-0.34	-0.84	-0.72	-0.73	0.72	0.36	-0.75	-0.86	-0.4	-0.61	-0.77		-0.72	-0.73	-0.86	-0.45	-0.89	0.66	-0.89	0.15	-0.77	-0.73	-0.74	-0.77	-0.53
Common Stock	0.89	0.86	0.95	0.61	0.72	-0.93	-0.2	0.83	0.86	0.46	0.95	0.85	-0.72		0.6	0.59	0.65	0.65	-0.79	0.66	-0.09	0.83	0.62	0.65	0.68	0.87
Property Plant Equipment	0.77	0.23	0.78	0.75	0.69	-0.6	-0.06	0.68	0.91	0.55	0.5	0.72	-0.73	0.6		0.64	0.71	0.66	-0.6	0.68	0.29	0.67	0.37	0.38	0.7	0.62
Short Long Term Debt Total	0.66	0.28	0.74	0.56	0.65	-0.54	-0.17	0.59	0.74	0.52	0.48	0.61	-0.86	0.59	0.64		0.17	0.99	-0.45	0.99	-0.31	0.59	0.89	0.88	0.75	0.31
Other Liab	0.66	0.49	0.64	0.58	0.49	-0.6	-0.18	0.64	0.67	0.13	0.56	0.66	-0.45	0.65	0.71	0.17		0.24	-0.67	0.26	0.39	0.64	0.1	0.17	0.39	0.71
Property Plant And Equipment Net	0.73	0.32	0.79	0.64	0.71	-0.58	-0.16	0.67	0.79	0.47	0.52	0.69	-0.89	0.65	0.66	0.99	0.24		-0.54	1.0	-0.32	0.68	0.91	0.9	0.8	0.37
Net Debt	-0.94	-0.59	-0.81	-0.91	-0.92	0.63	-0.1	-0.98	-0.79	-0.03	-0.63	-0.97	0.66	-0.79	-0.6	-0.45	-0.67	-0.54		-0.57	0.09	-0.98	-0.51	-0.52	-0.83	-0.65
Non Current Assets Total	0.76	0.34	0.8	0.67	0.74	-0.58	-0.11	0.69	0.8	0.48	0.53	0.71	-0.89	0.66	0.68	0.99	0.26	1.0	-0.57		-0.32	0.7	0.91	0.89	0.82	0.38
Non Currrent Assets Other	-0.07	-0.2	-0.1	-0.03	-0.17	-0.09	-0.29	-0.12	0.07	0.17	-0.03	-0.09	0.15	-0.09	0.29	-0.31	0.39	-0.32	0.09	-0.32		-0.13	-0.51	-0.46	-0.26	0.28
Cash And Short Term Investments	0.98	0.59	0.88	0.93	0.95	-0.68	0.05	1.0	0.86	0.15	0.67	1.0	-0.77	0.83	0.67	0.59	0.64	0.68	-0.98	0.7	-0.13		0.62	0.63	0.89	0.66
Common Stock Shares Outstanding	0.63	0.4	0.66	0.5	0.62	-0.49	-0.13	0.6	0.59	0.23	0.48	0.61	-0.73	0.62	0.37	0.89	0.1	0.91	-0.51	0.91	-0.51	0.62		0.99	0.68	0.26
Non Current Liabilities Total	0.63	0.45	0.68	0.48	0.59	-0.53	-0.19	0.61	0.6	0.23	0.52	0.61	-0.74	0.65	0.38	0.88	0.17	0.9	-0.52	0.89	-0.46	0.63	0.99		0.65	0.31
Capital Surpluse	0.9	0.43	0.83	0.91	0.97	-0.54	0.25	0.9	0.83	0.35	0.54	0.9	-0.77	0.68	0.7	0.75	0.39	0.8	-0.83	0.82	-0.26	0.89	0.68	0.65		0.48
Other Stockholder Equity	0.76	0.74	0.81	0.48	0.55	-0.93	-0.24	0.66	0.79	0.54	0.92	0.69	-0.53	0.87	0.62	0.31	0.71	0.37	-0.65	0.38	0.28	0.66	0.26	0.31	0.48

Click cells to compare fundamentals

Autolus Therapeutics Account Relationship Matchups

Autolus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	254.2M	294.2M	405.6M	490.3M	375.4M	279.3M
Other Current Liab	2.3M	496K	150K	40.8M	44.7M	2.2M
Total Current Liabilities	21.1M	33.6M	28.6M	46.4M	44.7M	24.3M
Total Stockholder Equity	232.6M	210.0M	313.3M	298.7M	111.5M	199.4M
Net Tangible Assets	232.6M	209.9M	313.3M	298.7M	267.5M	213.2M
Retained Earnings	(113.3M)	(379.2M)	(521.3M)	(670.2M)	(878.6M)	(119.0M)
Accounts Payable	2.0M	2.3M	431K	531K	103K	1.9M
Cash	217.5M	153.3M	310.3M	382.4M	239.6M	206.2M
Net Receivables	13.3M	29.7M	26.3M	29.0M	24.5M	18.5M
Other Current Assets	105K	43.7M	240K	203K	35.7M	99.8K
Total Liab	21.6M	84.2M	92.2M	191.6M	263.9M	20.5M
Total Current Assets	233.0M	197.0M	347.0M	425.8M	275.3M	231.8M
Intangible Assets	9.3M	254K	158K	65K	58.5K	55.6K
Common Stock	1.3K	2K	3K	4K	8K	3.3K
Property Plant Equipment	20.0M	89.7M	52.3M	58.4M	23.0M	36.1M
Short Long Term Debt Total	54.2M	21.0M	24.3M	53.0M	60.9M	64.0M
Other Liab	601K	492K	47.1M	126.0M	565.8K	537.5K
Property Plant And Equipment Net	89.7M	52.3M	58.4M	95.7M	110.0M	115.5M
Net Debt	(99.1M)	(289.3M)	(358.2M)	(186.6M)	(167.9M)	(176.3M)
Non Current Assets Total	97.3M	58.6M	64.5M	100.1M	115.1M	120.8M
Cash And Short Term Investments	217.5M	153.3M	310.3M	382.4M	239.6M	228.3M
Common Stock Shares Outstanding	51.6M	72.1M	95.0M	173.9M	200.0M	210.0M
Liabilities And Stockholders Equity	294.2M	405.6M	490.3M	375.4M	431.7M	312.1M
Non Current Liabilities Total	50.6M	63.7M	145.2M	219.2M	252.0M	264.6M
Other Stockholder Equity	(15.4M)	595.1M	843.2M	1.0B	1.0B	(14.6M)
Property Plant And Equipment Gross	20.0M	89.7M	75.0M	86.0M	124.4M	19.0M
Accumulated Other Comprehensive Income	(10M)	(5.9M)	(8.6M)	(38.9M)	(29.0M)	(10.5M)
Net Invested Capital	210.0M	313.3M	298.7M	111.5M	128.2M	249.3M
Net Working Capital	163.4M	318.4M	379.4M	230.6M	265.1M	266.4M
Inventory	(29.7M)	10.1M	14.2M	(24.5M)	(22.1M)	(21.0M)
Capital Lease Obligations	54.2M	21.0M	24.3M	53.0M	60.9M	39.3M
Short Term Debt	3.6M	4.5M	5.0M	5.1M	5.8M	4.5M

Pair Trading with Autolus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Autolus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Autolus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Autolus Stock

0.53	LIXT	Lixte Biotechnology Earnings Call This Week	Pair Corr
0.45	INDP	Indaptus Therapeutics Financial Report 9th of May 2024	Pair Corr
0.42	GBIO	Generation BioCo Financial Report 8th of May 2024	Pair Corr

The ability to find closely correlated positions to Autolus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Autolus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Autolus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Autolus Therapeutics to buy it.

The correlation of Autolus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Autolus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Autolus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Autolus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:

How To Invest In Autolus

Details

Is Autolus Stock a good investment?

Details

What is Autolus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Autolus Stock analysis

When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities

Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.20)

Revenue Per Share

0.01

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.25)

Return On Equity

(1.02)

The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Autolus Non Current Liabilities Total vs Return On Assets Analysis

Non Current Liabilities Total vs Return On Assets

Non Current Liabilities Total vs Return On Assets Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Return On Assets

Autolus Therapeutics fundamental ratios Correlations

Autolus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Autolus Therapeutics fundamental ratios Accounts

Pair Trading with Autolus Therapeutics

Moving against Autolus Stock

Complementary Tools for Autolus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Total Current Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total

Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.98	Cash
Net Debt	- 0.97	Total Current Assets
Total Liab	- 0.96	Retained Earnings
Net Debt	- 0.94	Total Assets
Other Stockholder Equity	- 0.93	Retained Earnings